Cyclacel Pharmaceuticals Stock Performance
| CYCC Stock | USD 0.35 0.01 2.94% |
The firm shows a Beta (market volatility) of 0.49, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Cyclacel Pharmaceuticals' returns are expected to increase less than the market. However, during the bear market, the loss of holding Cyclacel Pharmaceuticals is expected to be smaller as well. At this point, Cyclacel Pharmaceuticals has a negative expected return of -1.41%. Please make sure to confirm Cyclacel Pharmaceuticals' standard deviation, potential upside, day median price, as well as the relationship between the jensen alpha and accumulation distribution , to decide if Cyclacel Pharmaceuticals performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Cyclacel Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unfluctuating performance in the last few months, the Stock's fundamental indicators remain rather sound which may send shares a bit higher in December 2024. The latest tumult may also be a sign of longer-term up-swing for the firm shareholders. ...more
Last Split Factor 1:15 | Dividend Date 2020-04-15 | Last Split Date 2023-12-18 |
1 | Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter | 09/03/2024 |
2 | Acquisition by Walker Karin L of 2374 shares of Cyclacel Pharmaceuticals at 6.69 subject to Rule 16b-3 | 09/18/2024 |
3 | Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study | 09/25/2024 |
4 | StockNews.com Begins Coverage on Cyclacel Pharmaceuticals | 10/09/2024 |
5 | Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule | 10/24/2024 |
6 | Adherex Technologies Inc. Reports Q3 Loss, Misses Revenue Estimates | 11/07/2024 |
7 | Cyclacel Pharmaceuticals Announces Earnings Results | 11/13/2024 |
8 | Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for 2.1 Million Gross Proceeds | 11/14/2024 |
| Begin Period Cash Flow | 18.3 M | |
| Free Cash Flow | -16.1 M |
Cyclacel |
Cyclacel Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 104.00 in Cyclacel Pharmaceuticals on August 29, 2024 and sell it today you would lose (69.00) from holding Cyclacel Pharmaceuticals or give up 66.35% of portfolio value over 90 days. Cyclacel Pharmaceuticals is currently does not generate positive expected returns and assumes 7.7076% risk (volatility on return distribution) over the 90 days horizon. In different words, 68% of stocks are less volatile than Cyclacel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Cyclacel Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cyclacel Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Cyclacel Pharmaceuticals, and traders can use it to determine the average amount a Cyclacel Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1829
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CYCC |
Estimated Market Risk
| 7.71 actual daily | 68 68% of assets are less volatile |
Expected Return
| -1.41 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Cyclacel Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cyclacel Pharmaceuticals by adding Cyclacel Pharmaceuticals to a well-diversified portfolio.
Cyclacel Pharmaceuticals Fundamentals Growth
Cyclacel Stock prices reflect investors' perceptions of the future prospects and financial health of Cyclacel Pharmaceuticals, and Cyclacel Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cyclacel Stock performance.
| Return On Equity | -5.71 | ||||
| Return On Asset | -1.03 | ||||
| Operating Margin | (911.00) % | ||||
| Current Valuation | (819.2 K) | ||||
| Shares Outstanding | 6.29 M | ||||
| Price To Earning | (0.40) X | ||||
| Price To Book | 2.02 X | ||||
| Price To Sales | 27.98 X | ||||
| Revenue | 420 K | ||||
| Gross Profit | (455 K) | ||||
| EBITDA | (25.42 M) | ||||
| Net Income | (22.55 M) | ||||
| Cash And Equivalents | 29.08 M | ||||
| Cash Per Share | 2.32 X | ||||
| Total Debt | 37 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 6.38 X | ||||
| Book Value Per Share | 0.57 X | ||||
| Cash Flow From Operations | (16.11 M) | ||||
| Earnings Per Share | (26.48) X | ||||
| Market Capitalization | 2.24 M | ||||
| Total Asset | 8.8 M | ||||
| Retained Earnings | (428.28 M) | ||||
| Working Capital | (717 K) | ||||
| Current Asset | 24.57 M | ||||
| Current Liabilities | 5.75 M | ||||
About Cyclacel Pharmaceuticals Performance
By analyzing Cyclacel Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Cyclacel Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cyclacel Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cyclacel Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -74 K | -70.3 K | |
| Return On Tangible Assets | (2.56) | (2.43) | |
| Return On Capital Employed | (39.52) | (37.55) | |
| Return On Assets | (2.56) | (2.43) | |
| Return On Equity | (37.16) | (35.30) |
Things to note about Cyclacel Pharmaceuticals performance evaluation
Checking the ongoing alerts about Cyclacel Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Cyclacel Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cyclacel Pharmaceuticals generated a negative expected return over the last 90 days | |
| Cyclacel Pharmaceuticals has high historical volatility and very poor performance | |
| Cyclacel Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Cyclacel Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 420 K. Net Loss for the year was (22.55 M) with loss before overhead, payroll, taxes, and interest of (455 K). | |
| Cyclacel Pharmaceuticals currently holds about 29.08 M in cash with (16.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.32, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Cyclacel Pharmaceuticals has a poor financial position based on the latest SEC disclosures | |
| Latest headline from globenewswire.com: Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for 2.1 Million Gross Proceeds |
- Analyzing Cyclacel Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cyclacel Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Cyclacel Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cyclacel Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cyclacel Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Cyclacel Pharmaceuticals' stock. These opinions can provide insight into Cyclacel Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cyclacel Stock analysis
When running Cyclacel Pharmaceuticals' price analysis, check to measure Cyclacel Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cyclacel Pharmaceuticals is operating at the current time. Most of Cyclacel Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Cyclacel Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cyclacel Pharmaceuticals' price. Additionally, you may evaluate how the addition of Cyclacel Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data |